Although more U.S. hospitals are using high-sensitivity cardiac troponin (hs-cTn) assays to evaluate and manage patients with suspected acute coronary syndromes, a majority still do not use them, despite hs-cTn assays being the preferred biomarker to diagnose myocardial infarction (MI).